Abstract
Evidence for non-steroidal anti-inflammatory drugs (NSAIDs) preventing head and neck cancer (HNC) is inconclusive; however, there is some suggestion that aspirin may exert a protective effect.
Methods:Using data from the United States National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we examined the association between aspirin and ibuprofen use and HNC.
Results:Regular aspirin use was associated with a significant 22% reduction in HNC risk. No association was observed with regular ibuprofen use.
Conclusion:Aspirin may have potential as a chemopreventive agent for HNC, but further investigation is warranted.
| Original language | English |
|---|---|
| Pages (from-to) | 1178-1181 |
| Number of pages | 4 |
| Journal | British Journal of Cancer |
| Volume | 108 |
| Issue number | 5 |
| Early online date | 28 Feb 2013 |
| DOIs | |
| Publication status | Published - 19 Mar 2013 |
Bibliographical note
AcknowledgementsThis research was supported by contracts from the Division of Cancer Prevention, National Cancer Institute; NIH, DHHS. We thank Drs Christine Berg and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Centre investigators and staff of the PLCO Cancer Screening Trial; Mr Tom Riley and staff, Information Management Services, Inc.; Ms Barbara O’Brien and staff, Westat, Inc. Most importantly, we acknowledge the study participants for their contributions to making this study possible.
Keywords
- aspirin
- cohort study
- head and neck cancer
- ibuprofen
Access to Document
- Wilson_et_al_BJC_NonSteroidalAntiInflammatory_VoR
© 2013 Cancer Research UK. All rights reserved 0007 – 0920/13. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/